Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
Albert M. Maguire(Children's Hospital of Philadelphia), Jean Bennett(Penn Presbyterian Medical Center), Olga Zelenaia(Children's Hospital of Philadelphia), Francesca Simonelli(University of Naples Federico II), Kenneth S. Shindler(Penn Presbyterian Medical Center), Jeannette Bennicelli(Penn Presbyterian Medical Center), Bart P. Leroy(Ghent University Hospital), Arkady Lyubarsky(Penn Presbyterian Medical Center), Bernd Hauck(Children's Hospital of Philadelphia), Sandro Banfi(Telethon Institute Of Genetics And Medicine), T. Michael Redmond(National Institutes of Health), Eric A. Pierce(Massachusetts Eye and Ear Infirmary), Federico Mingozzi(Inserm), Francesco Testa(University of Naples Federico II), Leslie Raffini(Children's Hospital of Philadelphia), Jessica I. W. Morgan(Penn Presbyterian Medical Center), Junwei Sun(Singapore Management University), Katherine A. High(Spark Therapeutics (United States)), Frauke Coppieters(HOGENT University of Applied Sciences and Arts), J. Fraser Wright(Oxford BioMedica (United Kingdom)), Xiaosong Zhu(Linyi People's Hospital), Gui‐Shuang Ying(Philadelphia College of Osteopathic Medicine), Edwin M. Stone(Instituto da Visão), Carmela Acerra(University of Naples Federico II), Enrico Maria Surace(Telethon Institute Of Genetics And Medicine), Daniel C. Chung(Penn Presbyterian Medical Center), Settimio Rossi(University of Naples Federico II), Kathleen Marshall(Children's Hospital of Philadelphia), Ann Fulton(Boston Children's Hospital), Alberto Auricchio(Federico II University Hospital), Jennifer Wellman McDonnell(Children's Hospital of Philadelphia), Nicholas J. Volpe(Penn Presbyterian Medical Center)
Cited by 857
Related Papers
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
|Ophthalmology|2012|1.7k
Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1
|Nature Genetics|1993|1.7k
Gene therapy comes of age
|Science|2018|1.4k
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
|Proceedings of the National Academy of Sciences|1995|1.3k
Diabetic Retinopathy Preferred Practice Pattern®
|Ophthalmology|2019|703